University of Maryland, Baltimore hopes to treat cancer by inking a deal with Immunocellular Therapeutics to support three T-cell therapy-related projects.
University of Maryland, Baltimore has entered into a sponsored research agreement with immune-based cancer therapy developer Immunocellular Therapeutics, according to Smarter Analyst.
The agreement, made with Eduardo Davila, associate professor of microbiology and immunology, includes three projects aiming to improve cancer treatments. They focus on T-cells, a part of the human body’s own immune system, and their use in killing cancer cells.
Andrew Gengos, chief executive of Immunocellular, said: “With this agreement and with other related research underway, we are systematically delivering on our goal to build a leading cancer immunotherapy company. We are pleased with the enhanced position we are establishing in the dendritic cell and T-cell cancer immunotherapy space.”
Steven Swanson, senior vice-president for research at Immunocellular, said: “Immunocellular’s research and early development strategy is to complement and enhance our dendritic cell and stem-to-T-cell technology platforms and create potent cell-based cancer immunotherapeutic clinical candidates and combinations.
“The research projects we are undertaking with Dr Davila align well with this strategy and have the potential to lead to platform technology enhancements and new clinical programs.”
